Activity Two - Effective Documentation for Prescribing Opioids in Clinical Practice
Release Date: February 13, 2013
Expiration Date: February 13, 2014
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
Part two of a three-part accredited series of streaming video discussions between leading pain management experts focusing on topics that support risk minimization and safe and effective use of opioids. This second module will address effective documentation for prescribing opioids in a clinical practice.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in pain management.
Learning ObjectivesUpon completion of this educational activity, participants should be able to:
- Identify the six key elements which should be documented for all patients who are prescribed long-acting/extended-release (LA/ER) opioid therapy
- Describe the role of the treatment agreement in documentation for patients who are prescribed LA/ER opioids
- Outline the benefits of using risk assessment tools in patients prescribed LA/ER opioids
- Compare and contrast addiction versus aberrant behaviors, and identify the importance of documenting both in patients taking LA/ER opioids
Activity Two - Effective Documentation for Prescribing Opioids in Clinical Practice – Kenneth L. Kirsh, PhD (Moderator) and Steven D. Passik, PhD
Instructions for Participation and Credit
This activity is eligible for credit through February 13, 2014. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Kenneth L. Kirsh, PhD
Director of Behavioral Medicine
The Pain Treatment Center of the Bluegrass
Dr. Kenneth Kirsh received his PhD in clinical rehabilitation psychology from Indiana University-Purdue University Indianapolis. He is the director of behavioral medicine at The Pain Treatment Center of the Bluegrass (PTC) in Lexington, Kentucky, one of the largest freestanding, multidisciplinary pain centers in that region of the country. His duties also include work as a clinical psychologist and investigator in both investigator-initiated and clinical trials research.
Dr. Kirsh has given national and international invited lectures on pain and addiction, and most recently served as an assistant professor in pharmacy at the University of Kentucky, lecturing pharmacy students on behavioral medicine aspects of health care, cancer pain management, and substance abuse issues. He also was a previous assistant director for symptom management and palliative care at the Markey Cancer Center in Lexington. An author of more than 80 peer-reviewed and invited articles, Dr. Kirsh also has authored numerous book chapters, abstracts, and posters. He is a reviewer for more than 20 journals.
Steven D. Passik, PhD
Professor of Psychiatry and Anesthesiology
Vanderbilt University Medical Center
Dr. Steven Passik received his doctorate in clinical psychology from the New School for Social Research in New York City, and was chief fellow in the psychiatry service at Memorial Sloan-Kettering Cancer Center. Currently he is professor of psychiatry and anesthesiology at Vanderbilt University Medical Center in Nashville, Tennessee.
In 1999, Dr. Passik was a faculty scholar for the SOROS Foundation’s Project on Death in America. He has served on the editorial board of the Journal of Pain and Symptom Management, and has been a reviewer for the Journal of Pharmaceutical Care in Pain and Symptom Control, Journal of Pain and Symptom Management, Psycho-Oncology, Agency for Health Care Policy and Research Cancer Pain Guidelines, Cancer Investigation, and Oncology. Dr. Passik has served as the president of the Indiana Cancer and AIDS Pain Initiative and as editor in chief of the National Cancer Institute’s PDQ Supportive Care Editorial Board. He is the author of more than 120 journal articles, 60 book chapters, and 59 abstracts.
Dr. Passik was recently named a Fellow of DIV 28 of APA (Psychopharmacology & Substance Abuse), awarded a MayDay Fund Pain & Society Fellowship, given the academy of psychosomatic medicine Visiting Professor Award, and the American Psycho-Oncology Excellence in Clinical Care Award where he also serves on the advisory board. In addition, he received the Elizabeth Narcessian Award for Outstanding Educational Achievements. He speaks nationally and internationally on pain, addiction and the pain/addiction interface.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-13-341-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Kenneth Kirsh has received honoraria related to speakers’ bureau activities from King Pharmaceuticals, Inc. (now Pfizer Inc.), and PriCara®, Division of Janssen Pharmaceuticals, Inc.
Dr. Steven Passik has received honoraria related to speakers’ bureau activities from Ameritox, Ltd.; Cephalon, Inc.; Covidien; Endo Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Millennium Laboratories, LLC; Purdue Pharma L.P.; PharmacoFore; Pfizer Inc.; and Quest Diagnostics. He has received grant support related to research activities from Covidien.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director and Bronwyn Boyes, PharmD, director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Kirsh and Dr. Passik have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Kirsh and Dr. Passik have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Teva Pharmaceuticals.
©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.